Ceramide and ceramide 1-phosphate are negative regulators of TNF-α production induced by lipopolysaccharide.
LPS is a constituent of cell walls of Gram-negative bacteria that, acting through the CD14/TLR4 receptor complex, causes strong proinflammatory activation of macrophages. In murine peritoneal macrophages and J774 cells, LPS at 1-2 ng/ml induced maximal TNF-α and MIP-2 release, and higher LPS concentrations were less effective, which suggested a negative control of LPS action. While studying the mechanism of this negative regulation, we found that in J774 cells, LPS activated both acid sphingomyelinase and neutral sphingomyelinase and moderately elevated ceramide, ceramide 1-phosphate, and sphingosine levels. Lowering of the acid sphingomyelinase and neutral sphingomyelinase activities using inhibitors or gene silencing upregulated TNF-α and MIP-2 production in J774 cells and macrophages. Accordingly, treatment of those cells with exogenous C8-ceramide diminished TNF-α and MIP-2 production after LPS stimulation. Exposure of J774 cells to bacterial sphingomyelinase or interference with ceramide hydrolysis using inhibitors of ceramidases also lowered the LPS-induced TNF-α production. The latter result indicates that ceramide rather than sphingosine suppresses TNF-α and MIP-2 production. Of these two cytokines, only TNF-α was negatively regulated by ceramide 1-phosphate as was indicated by upregulated TNF-α production after silencing of ceramide kinase gene expression. None of the above treatments diminished NO or RANTES production induced by LPS. Together the data indicate that ceramide negatively regulates production of TNF-α and MIP-2 in response to LPS with the former being sensitive to ceramide 1-phosphate as well. We hypothesize that the ceramide-mediated anti-inflammatory pathway may play a role in preventing endotoxic shock and in limiting inflammation.
Laboratory of Plasma Membrane Receptors, Department of Cell Biology, Nencki Institute of Experimental Biology, Warsaw, Poland.
Szczepan
S
Józefowski
Maciej
M
Czerkies
Anna
A
Łukasik
Alicja
A
Bielawska
Jacek
J
Bielawski
Katarzyna
K
Kwiatkowska
Andrzej
A
Sobota
D000818:Animals; D002460:Cell Line; D002518:Ceramides / Q000378:metabolism / Q000502:physiology*; D054426:Chemokine CXCL2 / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D015536:Down-Regulation / Q000235:genetics / Q000276:immunology*; D005260:Female; D020868:Gene Silencing / Q000276:immunology; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors / Q000494:pharmacology / Q000502:physiology; D008070:Lipopolysaccharides / Q000037:antagonists & inhibitors / Q000502:physiology*; D008246:Lysophospholipids / Q000502:physiology; D017737:Macrophages, Peritoneal / Q000201:enzymology / Q000276:immunology / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics; D013110:Sphingosine / Q000031:analogs & derivatives / Q000502:physiology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000096:biosynthesis*
D002518:Ceramides; D054426:Chemokine CXCL2; C404915:Cxcl2 protein, mouse; D018836:Inflammation Mediators; D008070:Lipopolysaccharides; D008246:Lysophospholipids; D014409:Tumor Necrosis Factor-alpha; C065576:ceramide 1-phosphate; C060506:sphingosine 1-phosphate; D017853:Phosphotransferases (Alcohol Group Acceptor); C066324:ceramide kinase; D013110:Sphingosine